Evidence map›Paper›PMID 40993748›Full record

Trial reportOrphanet journal of rare diseases2025

Ziclague

Fabricio Diniz de Lima, Katiane Raisa Servelhere, Maria Fernanda Ribeiro Bittar, Carelis González-Salazar, Alberto Rolim Muro Martinez, Tatiana Benaglia, Benilton de Sá Carvalho, José Luiz Pedroso, Orlando Graziani Povoas Barsottini, Anamarli Nucci and 1 more

Abstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Orphanet journal of rare diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Fabricio Diniz de LimaDepartment of Neurology, University of Campinas (UNICAMP), Campinas, Brazil. fabriciodz@gmail.com.
Katiane Raisa ServelhereDepartment of Neurology, University of Campinas (UNICAMP), Campinas, Brazil.
Maria Fernanda Ribeiro BittarDepartment of Neurology, University of Campinas (UNICAMP), Campinas, Brazil.
Carelis González-SalazarDepartment of Neurology, University of Campinas (UNICAMP), Campinas, Brazil.
Alberto Rolim Muro MartinezDepartment of Neurology, University of Campinas (UNICAMP), Campinas, Brazil.
Tatiana BenagliaDepartment of Statistics, University of Campinas (UNICAMP), Campinas, Brazil.
Benilton de Sá CarvalhoDepartment of Statistics, University of Campinas (UNICAMP), Campinas, Brazil.
José Luiz PedrosoDepartment of Neurology, Federal University of São Paulo (UNIFESP), Sao Paulo, Brazil.
Orlando Graziani Povoas BarsottiniDepartment of Neurology, Federal University of São Paulo (UNIFESP), Sao Paulo, Brazil.
Anamarli NucciDepartment of Neurology, University of Campinas (UNICAMP), Campinas, Brazil.
Marcondes Cavalcante FrançaDepartment of Neurology, University of Campinas (UNICAMP), Campinas, Brazil. mcfjr@unicamp.br.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSpasticity is a hallmark of hereditary spastic paraplegia (HSP) and contributes to gait impairment. Alpinia zerumbet oil (Ziclague

methodsEach participant was randomly assigned to receive 0.8 mL of Ziclague

resultsFifty-seven patients were enrolled, 37 (64.9%) of whom were men and 50 (87.7%) with pure phenotype. Mean age was 44 (± 11.6; range, 22 to 74), mean age of onset 23 (± 16.6; range, < 1 to 62) and mean disease duration 21 (± 13.1; range, 2 to 54) years. Compared to baseline, there were no significant between-group differences in primary and secondary outcomes. There were few AEs, all of them mild. Incidence of AE was similar between treatment arms (p = 0.56).

conclusionsZiclague TRIAL REGISTRATION NUMBER: U1111-1218-2539. Registered 28 August 2018, https://ensaiosclinicos.gov.br/rg/RBR-83xh37 .

Indexed as

Spastic Paraplegia, HereditaryAdultCross-Over StudiesDouble-Blind MethodFemaleHumansMaleMiddle AgedQuality of LifeAlpinia zerumbetClinical trialGaitHereditary spastic paraplegiaSpasticity

Identifiers

PMID40993748
PMCPMC12462302

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.